Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Anlotinib + Sintilimab |
Indication/Tumor Type | cervical cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | cervical cancer | predicted - sensitive | Anlotinib + Sintilimab | Phase II | Actionable | In a Phase II study, a combination of Anlotinib (AL-3818) and Sintilimab (IBI308) resulted in an objective response rate of 54.8% (23/42, 2 complete responses and 21 partial responses) in CD274 (PD-L1)-positive recurrent or metastatic cervical cancer patients, and led to a disease control rate of 88.1% (37/42, 14 with stable disease), a median progression-free survival (PFS) of 9.4 mos and a 6-mo PFS rate of 73.1%, a median overall survival (OS) not reached, and a 12-mo OS rate of 73.8% (PMID: 35192397). | 35192397 |
PubMed Id | Reference Title | Details |
---|---|---|
(35192397) | Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial. | Full reference... |